npj Vaccines (Oct 2022)

Needle-free, spirulina-produced Plasmodium falciparum circumsporozoite vaccination provides sterile protection against pre-erythrocytic malaria in mice

  • Tracy Saveria,
  • Chaitra Parthiban,
  • Annette M. Seilie,
  • Colin Brady,
  • Anissa Martinez,
  • Ridhima Manocha,
  • Esha Afreen,
  • Hui Zhao,
  • Ashley Krzeszowski,
  • Jeremy Ferrara,
  • Troy Paddock,
  • James Roberts,
  • Brad C. Stone,
  • Michael Tasch,
  • Sean C. Murphy

DOI
https://doi.org/10.1038/s41541-022-00534-5
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Antibodies against the Plasmodium falciparum circumsporozoite protein (PfCSP) can block hepatocyte infection by sporozoites and protect against malaria. Needle-free vaccination strategies are desirable, yet most PfCSP-targeted vaccines like RTS,S require needle-based administration. Here, we evaluated the edible algae, Arthrospira platensis (commonly called ‘spirulina’) as a malaria vaccine platform. Spirulina were genetically engineered to express virus-like particles (VLPs) consisting of the woodchuck hepatitis B core capsid protein (WHcAg) displaying a (NANP)15 PfCSP antigen on its surface. PfCSP-spirulina administered to mice intranasally followed by oral PfCSP-spirulina boosters resulted in a strong, systemic anti-PfCSP immune response that was protective against subcutaneous challenge with PfCSP-expressing P. yoelii. Unlike male mice, female mice did not require Montanide adjuvant to reach high antibody titers or protection. The successful use of spirulina as a vaccine delivery system warrants further development of spirulina-based vaccines as a useful tool in addressing malaria and other diseases of global health importance.